ECE2013 Oral Communications Pituitary & Molecular Endocrinology (6 abstracts)
Management of euvolemic hyponatremia attributed to SIADH in the hospital: interim results from a prospective, observational, multi-center, global registry
Alessandro Peri 1 , Joseph Verbalis 2 , Arthur Greenberg 3 , Gudmundur Johannsson 4 , Steven Ball 5 , Jens Otto Jorgensen 6 & Joseph Chiodo 7
1University of Florence, Florence, Italy; 2Georgetown University, Washington, District of Columbia, USA; 3Duke University Medical Center, Durham, North Carolina, USA; 4University of Gothenburg, Gothenburg, Sweden; 5Newcastle University, Newcastle, UK; 6Aarhus University Hospital, Aarhus, Denmark, 7Otsuka America Pharmaceutical, Inc., Princeton, New Jersey, USA.
Introduction: Hyponatremia (HN) is the most common electrolyte disorder of hospitalized patients (pts). It occurs in up to 28% of in-pts, increases the in hospital risk of death by 1.47 fold, and is associated with significantly higher mortality risk following discharge. The HN Registry is the first large scale, international effort to document the clinical characteristics, treatments used, and impact of HN in hospital settings.
Methods: After informed consent or waiver, medical records of pts meeting the registry entry criteria were abstracted. Data are summarized by sample size (n) and percentage (%) for categorical data, and mean±S.D. for continuous data.
Results: One thousand seven hundred and six euvolemic pts with SIADH enrolled at 157 US and 93 EU sites from Sept 2010 to Dec 2012 had sufficient data for analysis. The mean entry and discharge [Na+] values for pts were 123.1±5.5 and 131.8±4.8 mmol/l. The table summarizes treatments given during hospitalization as treatment episodes of monotherapy (i.e. a treatment that was given alone during a discrete number of days).
| Treatment (Tx)* | During hospital stay (N) | Time to Tx from HN (days) | Duration of Tx (days) | (Na+) Correction rate (mmol/l per day) | (Na+) Increase >12 mmol/l within 24 h of Tx (%) |
| No treatment | 17% (285) | NA | NA | 1.1±1.3 | 2 |
| Fluid restriction | 56% (947) | 1.70±3.2 | 5.64±5.7 | 1.4±2.0 | 1 |
| Normal saline | 51% (862) | 0.75±2.1 | 2.67±2.4 | 2.0±2.8 | 2 |
| Hypertonic saline | 12% (212) | 1.74±3.1 | 2.37±1.9 | 4.2±4.0 | 11 |
| Tolvaptan | 17% (292) | 3.44±4.9 | 3.66±5.0 | 5.2±4.6 | 7 |
| *pts could have >1 treatment episode per hospitalization. | |||||
Conclusions: Fluid Restriction was minimally more effective than no treatment. Tolvaptan and hypertonic saline had the highest correction rates, but the latter was associated with a greater risk of overly rapid correction. More data is needed in this area to inform optimal clinical practice, which will be forthcoming from continuing analysis of the HN Registry.
Volume 32
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more